In Vivo Evaluation and Small-Animal PET/CT of a Prostate Cancer Mouse Model Using 64Cu Bombesin Analogs: Side-by-Side Comparison of the CB-TE2A and DOTA Chelation Systems.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2007 Jul 13; 48(8):1327-37
Garrison J JC, Rold T TL, Sieckman G GL, Figueroa S SD, Volkert W WA, Jurisson S SS,
Harry S. Truman Memorial VA Hospital, Columbia, Missouri; Department of Internal Medicine, Universit
The BB2 receptor subtype, of the bombesin family of receptors, has been shown to be highly overexpressed in a variety of human tumors, including prostate cancer. Bombesin (BBN), a 14-amino acid peptide, has been shown to target the BB2 receptor with high affinity. (64)Cu (half-life = 12.7 h, beta(+): 18%, Ebeta+max = 653 keV; beta(-): 37%, Ebeta-max = 578 keV) is a radioisotope that has clinical potential for application in both diagnostic imaging and radionuclide therapy. Recently, new chelation systems such as 1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid (CB-TE2A) have been reported to significantly stabilize the (64)Cu radiometal in vivo. The increased stability of the (64)Cu-CB-TE2A chelate complex has been shown to significantly reduce nontarget retention compared with tetraazamacrocycles such as 1,4,7,10-tetraazacyclodoadecane-N,N',N'',N'''-tetraacetic acid (DOTA). The aim of this study was to determine whether the CB-TE2A chelation system could significantly improve the in vivo stability of (64)Cu bombesin analogs. The study directly compares (64)Cu bombesin analogs using the CB-TE2A and DOTA chelation systems in a prostate cancer xenograft SCID (severely compromised immunodeficient) mouse model. METHODS: The CB-TE2A-8-AOC-BBN(7-14)NH2 and DOTA-8-AOC-BBN(7-14)NH2 conjugates were synthesized and radiolabeled with (64)Cu. The receptor-binding affinity and internalization profile of each metallated conjugate was evaluated using PC-3 cells. Pharmacokinetic and small-animal PET/CT studies were performed using female SCID mice bearing PC-3 xenografts. RESULTS: In vivo BB2 receptor targeting was confirmed by tumor uptake values of 6.95 +/- 2.27 and 4.95 +/- 0.91 %ID/g (percentage injected dose per gram) at the 15-min time point for the (64)Cu-CB-TE2A and (64)Cu-DOTA radioconjugates, respectively. At the 24-h time point, liver uptake was substantially reduced for the (64)Cu-CB-TE2A radioconjugate (0.21 +/- 0.06 %ID/g) compared with the (64)Cu-DOTA radioconjugate (7.80 +/- 1.51 %ID/g). The (64)Cu-CB-TE2A-8-AOC-BBN(7-14)NH2 radioconjugate demonstrated significant clearance, 98.60 +/- 0.28 %ID, from the mouse at 24 h after injection. In contrast, only 67.84 +/- 5.43 %ID of the (64)Cu activity was excreted using the (64)Cu-DOTA-8-AOC-BBN(7-14)NH2 radioconjugate because of nontarget retention. CONCLUSION: The pharmacokinetic and small-animal PET/CT studies demonstrate significantly improved nontarget tissue clearance for the (64)Cu-CB-TE2A8-AOC-BBN(7-14)NH2. This is attributed to the improved in vivo stability of the (64)Cu-CB-TE2A chelate complex as compared with the (64)Cu-DOTA chelate complex.